| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [2] |
Rahman R, Simoes EJ, Schmaltz C, et al. Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study[J]. Cancer Med, 2017, 6(4):874-880.
|
| [3] |
Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer[J]. Lancet, 2021, 397(10272):428-444.
|
| [4] |
Rawla P, Sunkara T, Thandra KC, et al. Epidemiology of gallbladder cancer[J]. Clin Exp Hepatol, 2019, 5(2):93-102.
|
| [5] |
Hickman L, Contreras C. Gallbladder cancer: diagnosis, surgical management, and adjuvant therapies[J]. Surg Clin North Am, 2019, 99(2):337-355.
|
| [6] |
Yoo C, Han B, Kim HS, et al. Multicenter phase Ⅱ study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J]. Cancer Res Treat, 2018, 50(4):1324-1330.
|
| [7] |
Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study[J]. J Clin Oncol, 2010, 28(30):4581-4586.
|
| [8] |
Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity[J]. Eur J Pharmacol, 2018, 834:188-196.
|
| [9] |
Oh DY, Bang YJ. HER2-targeted therapies-a role beyond breast cancer[J]. Nat Rev Clin Oncol, 2020, 17:33-48.
|
| [10] |
Leal P, García P, Sandoval A, et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma[J]. Arch Pathol Lab Med, 2013, 137(4):552-557.
|
| [11] |
Song X, Hu Y, Li Y, et al. Overview of current targeted therapy in gallbladder cancer[J]. Signal Transduct Target Ther, 2020, 5(1):230.
|
| [12] |
Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894.
|
| [13] |
Trabucco SE, Gowen K, Maund SL, et al. A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67, 000 patient samples[J]. J Mol Diagn, 2019, 21(6):1053-1066.
|
| [14] |
Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency[J]. Chin Clin Oncol, 2016, 5(5):62.
|
| [15] |
Lin J, Cao Y, Yang X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma[J]. Theranostics, 2021, 11(10):4585-4598.
|
| [16] |
Kassab J, Saba L, Gebrael G, et al. Update on immunotherapy in the management of gallbladder cancer[J]. Immunotherapy, 2023, 15(1):35-42.
|
| [17] |
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2015, 26(12):2375-2391.
|
| [18] |
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016, 27(4):559-574.
|
| [19] |
Guo Y, Feng K, Liu Y, et al. Phase Ⅰ study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers[J]. Clin Cancer Res, 2018, 24(6):1277-1286.
|
| [20] |
Rojas-Sepúlveda D, Tittarelli A, Gleisner MA, et al. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer[J]. Cancer Immunol Immunother, 2018, 67(12):1897-1910.
|
| [21] |
Kobayashi M, Sakabe T, Abe H, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer[J]. J Gastrointest Surg, 2013, 17(9):1609-1617.
|
| [22] |
Vermeulen Z, Segers VFM, De Keulenaer GW. ErbB2 signaling at the crossing between heart failure and cancer[J]. Basic Res Cardiol, 2016, 111(6):60.
|
| [23] |
Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications[J]. Mol Biol Int, 2014: 852748.
|
| [24] |
Mishra R, Patel H, Alanazi S, et al. HER3 signaling and targeted therapy in cancer[J]. Oncol Rev, 2018, 12(1):355.
|
| [25] |
Lenferink AE, Busse D, Flanagan WM, et al. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways[J]. Cancer Res, 2001, 61(17):6583-6591.
|
| [26] |
Nam AR, Kim JW, Cha Y, et al. Therapeutic implication of HER2 in advanced biliary tract cancer[J]. Oncotarget, 2016, 7(36):58007-58021.
|
| [27] |
Inagaki C, Maeda D, Kimura A, et al. Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: a case report[J]. World J Gastrointest Oncol, 2019, 11(9):761-767.
|
| [28] |
Prieto M, Gastaca M, Ruiz P, et al. Long term recurrence free survival in a stage Ⅳ gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection[J]. Ann Hepatobiliary Pancreat Surg, 2019, 23(4):403-407.
|
| [29] |
Ramanathan RK, Belani CP, Singh DA, et al. A phase Ⅱ study of lapatinib in patients with advanced biliary tree and hepatocellular cancer[J]. Cancer Chemother Pharmacol, 2009, 64(4):777-783.
|
| [30] |
Harding JJ, Piha-Paul SA, Shah RH, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers[J]. Nat Commun, 2023, 14(1):630.
|
| [31] |
Hadi R, Pant MC, Husain N, et al. EGFR and HER-2/neu expression in gallbladder carcinoma: an institutional experience[J]. Gulf J Oncolog, 2016, 1(20):12-19.
|
| [32] |
Mody K, Strauss E, Lincer R, et al. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report[J]. BMC Cancer, 2010, 10:570.
|
| [33] |
Philip PA, Mahoney MR, Allmer C, et al. Phase Ⅱ study of erlotinib in patients with advanced biliary cancer[J]. J Clin Oncol, 2006, 24(19):3069-3074.
|
| [34] |
Xu D, Li J, Jiang F, et al. The effect and mechanism of vascular endothelial growth factor (VEGF) on tumor angiogenesis in gallbladder carcinoma[J]. Iran J Public Health, 2019, 48(4):713-721.
|
| [35] |
Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study[J]. Lancet Oncol, 2010, 11(1):48-54.
|
| [36] |
Peluso I, Yarla NS, Ambra R, et al. MAPK signalling pathway in cancers: olive products as cancer preventive and therapeutic agents[J]. Semin Cancer Biol, 2019, 56: 185-195.
|
| [37] |
Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy[J]. Expert Opin Ther Targets, 2012, 16(1):103-119.
|
| [38] |
Kazmi HR, Chandra A, Nigam J, et al. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer[J]. Dig Surg, 2013, 30(3):233-239.
|
| [39] |
Li M, Chen L, Qu Y, et al. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing[J]. Oncotarget, 2017, 8(22):36319-36330.
|
| [40] |
Giannini I, Cutrignelli DA, Resta L, et al. Metastatic melanoma of the gallbladder: report of two cases and a review of the literature[J]. Clin Exp Med, 2016, 16(3):295-300.
|
| [41] |
Shu YJ, Weng H, Ye YY, et al. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway[J]. Mol Cancer, 2015, 14(1):12.
|
| [42] |
Costello BA, Borad MJ, Qi Y, et al. Phase Ⅰ trial of everolimus, gemcitabine and cisplatin in patients with solid tumors[J]. Invest New Drugs, 2014, 32(4):710-716.
|
| [43] |
Hwang IG, Jang JS, Do JH, et al. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients[J]. Cancer Chemother Pharmacol, 2011, 68(4):935-944.
|
| [44] |
Kim Y, Bang SS, Jee S, et al. Prevalence and clinicopathological significance of MET overexpression and gene amplification in patients with gallbladder carcinoma[J]. Cancer Res Treat, 2020, 52(2):481-491.
|
| [45] |
Li M, Liu F, Zhang F, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer:a whole-exome sequencing analysis[J]. Gut, 2019, 68(6):1024-1033.
|
| [46] |
王健东, 全志伟. 重视胆道恶性肿瘤化疗联合靶向免疫的综合治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(2):125-130.
|